Dobmeier Eric's Form 4 filing
Atara Biotherapeutics, Inc.ATRA · filed Nov 14, 2023
- Accession no.
- 0000905148-23-001449
- Filed
- Nov 14, 2023, 6:27 PM ET
- Trade date
- Nov 10, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $101.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dobmeier EricCIK 0001202785 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2023 | Common Stock | PPurchaseAcquired | +446,825 | $0.2268F1 | +$101,339.91 | 563,325 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2235 to $0.2298. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
Referenced by the price of 1 transaction in Table I.